{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:06:33Z","timestamp":1792343193977,"version":"4.4.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pathol.2017.09.006","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T06:47:05Z","timestamp":1511246825000},"page":"74-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":593,"title":["Diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"50","author":[{"given":"Shaoying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2017.09.006_bib1","series-title":"Tumors of the Hematopoeitic System","author":"Rappaport","year":"1966"},{"key":"10.1016\/j.pathol.2017.09.006_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(73)90469-8","article-title":"Characterisation of malignant mediastinal lymphoid neoplasm (Sternberg sarcoma) as thymic in origin","volume":"1","author":"Smith","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2017.09.006_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJM197404112901501","article-title":"Nodular lymphoma\u2014evidence for origin from follicular B lymphocytes","volume":"290","author":"Jaffe","year":"1974","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.09.006_bib4","first-page":"29","article-title":"Cytological and functional criteria for the classification of malignant lymphomata","volume":"2","author":"Lennert","year":"1975","journal-title":"Br J Cancer Suppl"},{"issue":"34 Suppl","key":"10.1016\/j.pathol.2017.09.006_bib5","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C","article-title":"Immunologic characterization of human malignant lymphomas","author":"Lukes","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2017.09.006_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00428-011-1083-0","article-title":"Classifications of lymphoma; reflections of time and technology","volume":"458","author":"Taylor","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2017.09.006_bib7","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2741\/4269","article-title":"The role of molecular biology in the diagnosis of lymphoid neoplasms","volume":"19","author":"Pizzi","year":"2014","journal-title":"Front Biosci"},{"key":"10.1016\/j.pathol.2017.09.006_bib8","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.pathol.2017.09.006_bib9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.09.006_bib11","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pathol.2017.09.006_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib13","article-title":"Concordant bone marrow\u00a0involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy","volume":"Jul 12","author":"Yao","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.09.006_bib14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2015-06-651968","article-title":"Discordant bone marrow involvement in non-Hodgkin lymphoma","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/PAP.0000000000000117","article-title":"Recent advances in aggressive large B-cell lymphomas: a comprehensive review","volume":"23","author":"Korkolopoulou","year":"2016","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0000000000000319","article-title":"Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations","volume":"39","author":"Horn","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/path.1485","article-title":"Differential Emu enhancer activity and expression of BOB.1\/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas","volume":"202","author":"Loddenkemper","year":"2004","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib18","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib19","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib20","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2005-02-0542","article-title":"Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma","volume":"106","author":"Tagawa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib21","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2005-07-2950","article-title":"Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas","volume":"107","author":"Chen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib22","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"Aug 14","author":"Karube","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.09.006_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM199407143310202","article-title":"Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma","volume":"331","author":"Offit","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.09.006_bib24","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","article-title":"Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma","volume":"92","author":"Kramer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib25","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2017.09.006_bib26","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2017.09.006_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.09.006_bib28","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.09.006_bib29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","article-title":"Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis","volume":"33","author":"Dybk\u00e6r","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2017.09.006_bib31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.09.006_bib32","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma","volume":"3","author":"Clozel","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2017.09.006_bib33","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood-2012-05-430389","article-title":"A\u00a0new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma","volume":"120","author":"Perry","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.09.006_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.09.006_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.09.006_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.09.006_bib39","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2017.09.006_bib40","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41598-017-01998-5","article-title":"Clinopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2017.09.006_bib41","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib42","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.09.006_bib43","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"12","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib44","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib45","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/PAS.0000000000000836","article-title":"Anaplastic variant of diffuse large B-cell lymphoma displays intricate genetic alterations and distinct biological features","volume":"41","author":"Li","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib46","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1080\/10428194.2017.1287364","article-title":"Does cell-of-origin or MYC, BCL2 or PCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review","volume":"58","author":"Schmidt-Hansen","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2017.09.006_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib48","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A\u00a0new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2017.09.006_bib49","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.09.006_bib50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2017.09.006_bib51","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/path.1924","article-title":"Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma","volume":"208","author":"Muris","year":"2006","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib52","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","article-title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","volume":"109","author":"Nyman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib53","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2017.09.006_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pathol.2017.09.006_bib56","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib57","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/cncr.26433","article-title":"Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2017.09.006_bib58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.14282","article-title":"Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable","volume":"175","author":"Landsburg","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/PAS.0000000000000542","article-title":"High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis","volume":"40","author":"Li","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib60","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1002\/cncr.30895","article-title":"C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: impact of additional \u201chits\u201d and outcomes with subsequent therapy","volume":"123","author":"Epperla","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2017.09.006_bib61","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ejh.12212","article-title":"MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC\/BCL2 translocations","volume":"92","author":"Pedersen","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib63","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0000000000000818","article-title":"Further exploration of the complexities of large B-cell lymphomas with MYC abnormalities and the importance of a blastoid morphology","volume":"41","author":"Moore","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib64","doi-asserted-by":"crossref","first-page":"18374","DOI":"10.18632\/oncotarget.4073","article-title":"MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2017.09.006_bib65","article-title":"Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma","volume":"Aug 4","author":"Quesada","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome,irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.09.006_bib67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.anndiagpath.2016.07.008","article-title":"Aggressive B-cell lymphomas: frequency, immunophenotype, and genetics in a reference laboratory population","volume":"25","author":"Naeini","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib68","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib69","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/PAS.0000000000000434","article-title":"Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations\/rearrangements: clinicopathologic features of 11 cases","volume":"39","author":"Wang","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib70","doi-asserted-by":"crossref","first-page":"38122","DOI":"10.18632\/oncotarget.9473","article-title":"Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC\/BCL2 double hit lymphoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2017.09.006_bib71","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.29781","article-title":"Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma","volume":"122","author":"Landsburg","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2017.09.006_bib72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/modpathol.3800500","article-title":"Lymphoid neoplasms associated with concurrent t(14;18) and 8q24\/c-MYC translocation generally have a poor prognosis","volume":"19","author":"Kanungo","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib73","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.11305","article-title":"The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement","volume":"92","author":"Le Gouill","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.09.006_bib74","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2008.005355","article-title":"Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations","volume":"94","author":"Tomita","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.09.006_bib75","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.09.006_bib77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.2012.01787.x","article-title":"Double-hit BCL2\/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma \u2013 a single centre's experience","volume":"89","author":"Pedersen","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib79","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3324\/haematol.11263","article-title":"High-grade B-cell lymphoma\/leukemia associated with t(14;18) and 8q24\/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis","volume":"92","author":"Lin","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.09.006_bib80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib81","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2017.09.006_bib82","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib83","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1309\/AJCPBWVHTF7RRSA4","article-title":"Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics","volume":"142","author":"Turakhia","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib85","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/his.12884","article-title":"MYC\/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis","volume":"68","author":"Li","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2017.09.006_bib86","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":"Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma","volume":"99","author":"Aukema","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.09.006_bib87","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/modpathol.2014.95","article-title":"B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas","volume":"28","author":"Li","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib88","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2017.09.006_bib89","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib90","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/PAS.0000000000000433","article-title":"MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC\/BCL2 protein double-positive diffuse large B-cell lymphoma","volume":"39","author":"Wang","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib91","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib92","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM199708213370804","article-title":"Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma","volume":"337","author":"Ichikawa","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.09.006_bib93","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1080\/10428190410001713170","article-title":"Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature","volume":"45","author":"Kerbauy","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2017.09.006_bib94","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib95","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428194.2014.907896","article-title":"TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations","volume":"56","author":"Gebauer","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2017.09.006_bib96","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1309\/AJCPPHMZ6VHF0WQV","article-title":"p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study","volume":"141","author":"Xie","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib97","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/modpathol.2016.178","article-title":"P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma","volume":"30","author":"Wang","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib98","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cjp2.10","article-title":"The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit","volume":"1","author":"Clipson","year":"2015","journal-title":"J\u00a0Pathol Clin Res"},{"key":"10.1016\/j.pathol.2017.09.006_bib99","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib100","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.18632\/oncotarget.3479","article-title":"Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries","volume":"6","author":"Xu-Monette","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2017.09.006_bib101","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1182\/blood-2002-05-1525","article-title":"Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production","volume":"100","author":"Gary-Gouy","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.09.006_bib102","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4049\/jimmunol.168.1.232","article-title":"CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif","volume":"168","author":"Gary-Gouy","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2017.09.006_bib103","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajh.24299","article-title":"De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort","volume":"91","author":"Alinari","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib104","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ejh.12847","article-title":"Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH","volume":"98","author":"Thakral","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11899-016-0345-y","article-title":"CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas","volume":"11","author":"Bhatt","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.pathol.2017.09.006_bib106","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.13085","article-title":"CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia","volume":"167","author":"Slack","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/ejh.12680","article-title":"CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma","volume":"97","author":"Wang","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib108","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2016.10.009","article-title":"CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma","volume":"60","author":"Xu","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2017.09.006_bib109","article-title":"Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances","volume":"Jun 13","author":"Epperla","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.pathol.2017.09.006_bib110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2017.09.006_bib111","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3109\/10428194.2014.941836","article-title":"Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era","volume":"56","author":"Bohers","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2017.09.006_bib112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-017-0449-1","article-title":"Molecular subtyping in diffuse large B cell lymphoma: closer to approach of precision therapy","volume":"18","author":"Karmali","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.pathol.2017.09.006_bib113","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2017.09.006_bib114","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302517304713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302517304713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:23:19Z","timestamp":1758471799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302517304713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0031302517304713"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}